Taysha gene therapies announces pivotal part b trial design details for tsha-102 in rett syndrome enabled by irsf natural history data and positive clinical data from part a of the reveal adult/adolescent and pediatric trials evaluating tsha-102

Natural history data analysis established patients ≥ six years of age are in developmental plateau, with a ~0% likelihood of gaining/regaining developmental milestones across the core functional domains of rett syndrome
TSHA Ratings Summary
TSHA Quant Ranking